Agios Pharmaceuticals: Worthy Of Accumulation [Seeking Alpha]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Seeking Alpha
AGIO's recent FDA approval for mitapivat in thalassemia expands its addressable market, supporting the investment thesis. The company maintains a fortress balance sheet with $1.2 billion in cash, no long-term debt, and a recent $300 million annual cash burn. Analyst sentiment has turned somewhat positive post-Q4 results, reinforcing an accumulation case for risk-tolerant investors. An updated analysis around Agio Pharmaceuticals follows in the paragraphs below. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » vdvornyk/iStock via Getty Images When I last looked at Agios Pharmaceuticals ( AGIO in mid-June of last year, I concluded that article noting that Agios had a fortress balance sheet. The stock merited a ' Speculative Buy ' rating for risk-tolerant investors. The shares moved More on my IG service Live Chat on The Biotech Forum sees frequent discussion of specific covered
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIOPR Newswire
- Agios Pharmaceuticals (AGIO) had its price target raised by Citigroup Inc. from $38.00 to $46.00. They now have a "buy" rating on the stock.MarketBeat
- How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets [Yahoo! Finance]Yahoo! Finance
- Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIOPR Newswire
- Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIOPR Newswire
AGIO
Earnings
- 2/12/26 - Miss
AGIO
Sec Filings
- 3/9/26 - Form 4
- 3/5/26 - Form 144
- 3/5/26 - Form 4
- AGIO's page on the SEC website